4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics (FDMT), a late-stage biotechnology company, has announced its participation in two major upcoming investor conferences in June 2025. The company's management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 4 at 3:45 p.m. ET and the Goldman Sachs Global Healthcare Conference on June 11 at 11:20 a.m. ET. One-on-one meetings with management will be available, and webcasts of the presentations will be accessible for up to one year on the company's investor relations website.
4D Molecular Therapeutics (FDMT), un'azienda biotecnologica in fase avanzata, ha annunciato la sua partecipazione a due importanti conferenze per investitori previste per giugno 2025. Il management della società parteciperà a discussioni informali al Jefferies Global Healthcare Conference il 4 giugno alle 15:45 ET e al Goldman Sachs Global Healthcare Conference l'11 giugno alle 11:20 ET. Saranno disponibili incontri individuali con il management e le presentazioni saranno trasmesse in webcast, accessibili fino a un anno sul sito web delle relazioni con gli investitori della società.
4D Molecular Therapeutics (FDMT), una empresa biotecnológica en etapa avanzada, ha anunciado su participación en dos importantes conferencias para inversores que se celebrarán en junio de 2025. La dirección de la empresa participará en charlas informales en la Jefferies Global Healthcare Conference el 4 de junio a las 3:45 p.m. ET y en la Goldman Sachs Global Healthcare Conference el 11 de junio a las 11:20 a.m. ET. Habrá reuniones individuales con la dirección y las presentaciones estarán disponibles en webcast durante hasta un año en el sitio web de relaciones con inversores de la empresa.
4D Molecular Therapeutics (FDMT)는 후기 단계의 생명공학 회사로서 2025년 6월에 열리는 두 개의 주요 투자자 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 6월 4일 오후 3시 45분(동부시간)에 Jefferies Global Healthcare Conference에서, 6월 11일 오전 11시 20분(동부시간)에 Goldman Sachs Global Healthcare Conference에서 대담에 참여할 예정입니다. 경영진과의 일대일 미팅도 가능하며, 발표 내용은 회사 투자자 관계 웹사이트에서 최대 1년간 웹캐스트로 제공됩니다.
4D Molecular Therapeutics (FDMT), une entreprise biotechnologique en phase avancée, a annoncé sa participation à deux grandes conférences pour investisseurs prévues en juin 2025. La direction de l'entreprise participera à des discussions informelles lors de la Jefferies Global Healthcare Conference le 4 juin à 15h45 ET et lors de la Goldman Sachs Global Healthcare Conference le 11 juin à 11h20 ET. Des rencontres individuelles avec la direction seront possibles, et les webcasts des présentations seront accessibles pendant un an sur le site des relations investisseurs de la société.
4D Molecular Therapeutics (FDMT), ein biotechnologisches Unternehmen in der Spätphase, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Juni 2025 angekündigt. Das Management des Unternehmens wird am Jefferies Global Healthcare Conference am 4. Juni um 15:45 Uhr ET und am Goldman Sachs Global Healthcare Conference am 11. Juni um 11:20 Uhr ET in informellen Gesprächen teilnehmen. Einzelgespräche mit dem Management sind möglich, und Webcasts der Präsentationen werden bis zu einem Jahr auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
EMERYVILLE, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in June. Members of the management team will also be available for one-on-one meetings.
Jefferies Global Healthcare Conference
| Presentation Date: | Wednesday, June 4, 2025 |
| Presentation Time: | 3:45 p.m. ET |
| Webcast Link: | Webcast |
Goldman Sachs Global Healthcare Conference
| Presentation Date: | Wednesday, June 11, 2025 |
| Presentation Time: | 11:20 a.m. ET |
| Webcast Link: | Webcast |
An archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Our lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Our lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. Our second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
FAQ
When is 4D Molecular Therapeutics (FDMT) presenting at the Jefferies Healthcare Conference 2025?
What time is FDMT's presentation at the Goldman Sachs Healthcare Conference 2025?
How long will FDMT's conference webcasts be available for viewing?
Where can investors access FDMT's conference presentation webcasts?
